Effects of keratin filaments on ERK signaling during Fas-induced death of cervical cancer (HeLa) cells by Berger, Amanda
University of New Hampshire
University of New Hampshire Scholars' Repository
Honors Theses and Capstones Student Scholarship
Spring 2014
Effects of keratin filaments on ERK signaling during
Fas-induced death of cervical cancer (HeLa) cells
Amanda Berger
University of New Hampshire - Main Campus, ajj94@wildcats.unh.edu
Follow this and additional works at: https://scholars.unh.edu/honors
Part of the Cancer Biology Commons
This Senior Honors Thesis is brought to you for free and open access by the Student Scholarship at University of New Hampshire Scholars' Repository.
It has been accepted for inclusion in Honors Theses and Capstones by an authorized administrator of University of New Hampshire Scholars'
Repository. For more information, please contact nicole.hentz@unh.edu.
Recommended Citation
Berger, Amanda, "Effects of keratin filaments on ERK signaling during Fas-induced death of cervical cancer (HeLa) cells" (2014).





Effects of keratin filaments on ERK signaling during 
Fas-induced death of cervical cancer (HeLa) cells 
 




Undergraduate: Amanda Berger 
Major: Biomedical Science, Medical and Veterinary Option 
 
Faculty Advisor: Dr. David H. Townson 






Table of Contents 
Abstract…1 
Introduction…2 





Appendix I: Treatment Diagram for 6-well Culture Plates…20 
Appendix II: Cell Lysates Protocol…21 
Appendix III: Western Blotting Protocol…22 
Appendix IV: Immunodetection Protocol…23 
Appendix V: Treatment Diagram for 96-well Culture Plates…24 
Appendix VI: In-Cell Western Protocol…25 














 Survival of cancer cells is influenced by a variety of factors, including physical elements 
such as keratin filaments. We know HeLa cells containing or lacking keratin 8/18 intermediate 
filaments (K+ and K- cells, respectively) are more sensitive to the death-inducing effects of Fas 
agonist compared to the cytokines tumor necrosis factor alpha (TNF-α) or TNF-related 
apoptosis-inducing ligand. Additionally, K- cells are more sensitive to Fas-induced death than 
K+ as shown by previous studies using mitochondrial activity and caspase activation assays. In 
the current study we tested the hypothesis that keratin filaments associate with the mitogen 
activated protein kinase (MAPK) cascade to protect cells from Fas-induced death. To do this, K+ 
and K- cells were exposed to Fas agonist in the absence or presence of human epidermal growth 
factor (EGF) (known to stimulate MAPK) and then downstream phosphorylation of extracellular 
signal-regulated kinase (pERK) was measured. Fas agonist reduced pERK expression in both 
cell types (~32% less pERK compared to non-EGF-treated controls, n= 3 expts.).  Conversely, 
EGF (50ng/ml) reversed this outcome, but again did so equally in K+ and K- cells. Intriguingly, 
K- cells were more responsive to EGF stimulation alone than K+ cells, regardless of EGF dose 
(pERK ~27% higher in K- than K+ cells, n= 3 expts.).  The results suggest keratin 8/18 filaments 
do associate with the MAPK cascade to influence cell survival. Supported by the Hamel Center 










Cancer cell persistence can be attributed to any number of various factors. Infection by 
viruses, for example, causes changes in genotype that can disrupt cellular mechanisms triggering 
apoptosis. Many mechanisms exist to cause cancer, but some are more common than others. 
Cervical cancer remains the second most common cancer among females worldwide (20). The 
incidence rate varies by country, from 2 percent of women affected in the United States to as 
high as 50 percent of women affected in Guinea 10. On average, 500,000 women develop cervical 
cancer annually, of which 99 percent arise from infection by the human papillomavirus, or HPV 
20, 18, 25
. Over 40 different strains of HPV exist that infect the genital areas of men and women 18.  
Infected tissues include, but are not limited to, the cervix, vagina, penis, and rectum 18. In 
particular, HPV strains 16 and 18 are especially high-risk because they cause approximately 70 
percent of all cervical cancers 18, 25. Although 90 percent of HPV infections are generally 
resolved by attack from the body’s immune system, HPV 16 and 18 are especially persistent and 
can result in cervical cancer 18. 
HeLa Cells as a Research Subject 
 Among the more widely-known types of HPV-infected cells associated with cervical 
cancer, HeLa cells (derived from the cervical tumor of Ms. Henrietta Lacks in 1951) have been 
extensively studied 27. The HeLa cell line, infected with HPV strain 18, is a particularly 
aggressive cancer cell and continues to thrive in laboratories worldwide today 24, 27. 
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 The HeLa cells used in the current project consist of two readily apparent phenotypes: 
cells that express cytokeratin 8/18 (K8/18) intermediate filaments and cells that do not. Although 
these filaments are known to provide structural integrity to cells, in recent years it has been 
demonstrated that they also prevent apoptosis 9, 28. 
Cytokeratin Intermediate Filaments 
 Cytokeratin 8/18 filaments are expressed in a multitude of epithelial organs. The proteins 
are essential structural components of epithelial cells that form a network of filaments within the 
cytoplasm 12. They help cells resist external pressures, maintain normal mitochondrial function, 
and regulate cellular functions such as mitosis, apoptosis, and cell signaling 12, 14. Because of 
their varied functions within the cell, cytokeratin filaments are suspected to play an integral role 
in cancer development 7, 14, 17. 
 Although the components of cytokeratins are highly conserved across species, they 
generally consist of at least 20 different gene products which can be arranged into a relatively 
acidic, Type I group (cytokeratins 9 through 20) and a neutral–basic, Type II group (cytokeratins 
1 through 8) 14, 17. Cytokeratins exist as heterodimers in a 1:1 ratio of acidic and neutral-basic 
proteins, which then form filamentous polymers, such as cytokeratin 8/18 14, 17.  Expression of 
these proteins is cell-specific and can be influenced by the degree of cell differentiation. For 
instance, as cancer cells become less differentiated, cytokeratin expression is often a useful 





Effects of ERKs and Cytokeratins on Apoptosis 
The ability of K8/18 filaments to interfere with immune-mediated apoptosis is considered 
one mechanism contributing to the development of epithelial cell carcinomas 23.  The K8/18 
filaments may prevent apoptosis through a variety of cellular mechanisms, including the 
upregulation of growth/differentiation pathways that counteract the effects of immune attack 19, 6, 
21
.  Based upon previous work by others in which K8/18 filaments provided a protective effect in 
epithelial cells, we postulate that K8/18 filaments provide analogous protection from cytokine-
mediated apoptosis in cervical cancer cells. 
The extrinsic pathway of apoptosis in cells is predicated on the actions of cytokines such 
as Fas ligand to activate initiator and executor caspases within the cell, which in turn provoke 
cell death 11, 32. In Fas ligand-induced apoptosis, Fas ligand binds to its receptor to activate the 
Fas-associated death domain protein (FADD), that activates downstream proteins including 
caspase 8, and executor caspases 3 and 7 11, 32. Caspases 3 and 7 initiate apoptosis downstream 
along with Smac/DIABLO and other downstream pro-apoptotic proteins 11, 15, 29.  
The mechanisms by which K8/18 filaments promote anti-apoptotic effects within cell are 
not entirely clear, but may include activation of the MAP kinase cascade to overcome Fas-
induced death-signaling. The scaffolding provided by K8/18 filaments supports activation of 
Raf-1, the first kinase in the MAP kinase cascade 29. Raf-1 activates MEK 1/2, which then 
activates ERK 1/2 through phosphorylation 29. The collective actions of phosphorylated ERK 






 Decreased expression of phosphorylated extracellular-regulated kinases in HeLa cells 
renders them more sensitive to cytokine-induced apoptosis 30. Conversely, increased levels of 
phosphorylated ERK protect cells by suppressing caspase activation and subsequent apoptosis 
when exposed to these same cytokines 30. 
 To investigate this phenomenon further, an experiment was conducted in spring 2013 to 
determine if cytokeratin 8/18 filament expression in HeLa cells affects caspase activation after 
the cells are exposed to cytokines. Cultures of HeLa cells possessing and lacking cytokeratin 
8/18 filaments (K+ and K- cells) were grown in 96-well plates for dose-response experiments 
involving several different cytokines.  The cells were treated with TNF-α, TRAIL, or Fas agonist 
to determine the dose and type of cytokine most effective at inducing apoptosis.  The cytokines 
TNF-α and TRAIL had essentially no effect on the two phenotypes, failing to induce caspase 
activity above non-cytokine-treated controls.   However, Fas agonist did induce caspase activity 
in the cells, and K+ HeLa cells were more resistant to Fas-induced apoptosis than K- HeLa cells, 
as expected.  
Immunodetection of ERK in K+ and K- HeLa cells 
 Following the above-described cytokine dose-response experiments, a subsequent 
experiment was conducted to determine the effect of K8/18 filaments on MAPK activation by 
measuring relative ERK expression. An initial set of samples collected in the summer 2013 
indicated that ERK expression was present for both K+ and K- cells. Phosphorylated ERK 
expression was highest in K- cells treated with hEGF, but other treatment conditions did not 
appear to yield higher amounts of pERK for either phenotype. Unfortunately, subsequent 
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attempts to analyze ERK expression failed to provide consistent results. Explanations for the 
inconsistencies include inaccurate protein loading during electrophoresis, unsuitable antibody 
incubation solutions, and possibly other factors interfering with secondary antibody detection.   
 To address these problems, a standardized protocol was devised, and immunodetection 
experiments were repeated in fall 2013 3, 21. In this run of western blots, the background was 
reduced and quantification of bands showed that K- cells exposed to hEGF exhibited greater 
ERK expression than any other treatment condition. We expected K+ cells to express greater 
amounts of ERK when treated with Fas agonist compared to K- cells treated with the same 
cytokine, but similar ERK expression was exhibited by both phenotypes after treatment with Fas 
agonist. Furthermore, pERK/totERK expression was inconsistent for K+ and K- negative control 
conditions, which indicates that conclusions cannot be drawn from these results alone due to the 
inconsistency of our control conditions. 
 In summary, there was no difference in ERK 1/2 expression between K+ and K- 
phenotypes, especially following treatment with Fas agonist.  In fact the only indication that 
K8/18 filaments influenced MAPK activation in the HeLa cells in the current experiments stems 
from finding that hEGF-stimulated  ERK 1/2 expression is greater in K- cells than K+ cells. This 
finding and inconsistencies in our control conditions necessitated that we repeat these 
experiments using alternate detection methods to determine if higher ERK 1/2 expression in  K- 
cells following Fas agonist treatment was a result of inaccurate immunodetection or actual 
differences in ERK expression between the two phenotypes following Fas agonist treatment. 
 The above inconsistencies in methods and findings prompted us to repeat the Fas agonist 
and hEGF experiments using an alternative, in-cell western immunofluorescent assay for 
immunodetection 1, 2, 4, 21. The rationale was that during western blot immunodetection, protein 
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loss occurs at many stages; including lysate transfer from culture plate to microfuge tube, 
removal of cell debris following centrifugation, and protein transfer from gel to PVDF 
membrane 21.  Any one of these losses could confound potential differences in protein detection 
between K+ and K- cell preps. The in-cell western assay, alternatively, offers more quantitative 
results with less protein loss 21. Thus, additional experiments were conducted using this format 
for protein detection. Again, we hypothesized that K8/18 filaments promote anti-apoptotic 
effects within HeLa cells by activation of the MAPK cascade to overcome Fas-induced death-
signaling.  Measurement of phosphorylated extracellular-regulated kinases (pERK) was used as 
an indication of MAP kinase activation. 
Expected Outcomes and Interpretations 
 The results of the in-cell western assays could partly determine if the western blotting 
experiments performed in summer 2013 were an anomaly or if they provide further evidence to 
reject the current hypothesis. In-cell western assays were anticipated to show elevated 
phosphorylated ERK 1/2 expression in K+ compared to K- HeLa cells, especially under 
conditions of Fas agonist treatment. An additional hope was that in-cell western assays would 










Materials and Methods 
 
Western Blot Immunodetection 
 Two different HeLa strains, K+ and K- cells, were grown under sterile culture conditions. 
At 70 percent confluency, the cells were trypsinized and passaged into 6-well plates at a seeding 
concentration of 80,000 cells per mL until confluency of 70 percent or greater was again 
achieved. At this point the cultures were then treated with human epidermal growth factor 
(hEGF) as a positive control, Fas ligand as the experimental variable, or vehicle as the negative 
control (Appendix I). Following a 10 minute incubation period, the treatments were rinsed and 
removed from the cells. The cells were then scraped from the bottom of the wells in lysis buffer, 
lysed with a 28 gauge needle, and transferred into centrifuge tubes. After centrifugation the 
supernatant (containing proteins such as pERK) was separated from the cell debris in the pellet   
Protein concentration of the supernatant was measured and the remaining sample was mixed 
with 5X or 2X Sample Buffer, Heated, and frozen at -80°C until further use (see detail-Appendix 
II). 
 Once samples were prepared as described above, they were loaded into polyacrylamide 
gels for protein separation via electrophoresis. Following size separation via electrophoresis, the 
proteins in the gel were transferred to a polyvinylidene fluoride (PVDF) membrane (Appendix 
III). Following transfer, the membrane was incubated overnight at 4C with primary antibodies 
that bind to phosphorylated ERK 1/2 and total ERK, and then probed with fluorescent secondary 
antibodies Dylight 680 and Dylight 800 for a half hour (Appendix IV).  A LI-COR Odyssey 
infra-red imaging system was used to detect secondary antibodies at 700 nm and 800 nm 
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wavelengths. Protein content was quantified using Image Studio Lite software and MS Excel 
software aided in generation of statistical data and graphs. 
In-Cell Western Immunodetection 
In-cell western immunodetection was also performed using K+ and K- strains of HeLa 
cells. Three in-cell western assays were performed with treatments added in triplicate for each 
individual experiment. The HeLa cells were first grown as previously described prior to seeding 
in 96-well plates. At 70 percent confluency, the cells were treated with increasing doses of hEGF 
and without or with Fas agonist. The concentrations used were 5, 10, and 50 ng/mL EGF, 1 
µg/mL Fas agonist, and 50 ng/mL hEGF plus1 µg/mL Fas agonist (Appendix V). Within 10 
minutes of treatment, the cells were rinsed and then fixed with 100% methanol in preparation for 
in-cell western assay (Appendix VI). Briefly, the fixative was removed and the wells were 
blotted dry. Subsequently the wells were rinsed three times for 5 minutes each with tris-buffered 
saline (TBS), blocked for one hour with blocking buffer and then incubated with ERK 1/2 and 
total ERK primary antibodies The plate was incubated overnight at 4°C. 
Following primary antibody incubation, the wells were rinsed three times for 5 minutes 
each with TBS and then fluorochrome-conjugated secondary antibody was added to the plate and 
incubated for one hour at room temperature in the dark (Appendix VI). The plate was again 
rinsed three times for 5 minutes each with TBS and then scanned with a LiCor Odyssey infra-red 
imaging system at 700 and 800 nm wavelengths to visualize phosphorylated ERK and total ERK 
proteins. Proteins were quantified using Image Studio Lite software and MS Excel software 






 The western blot immunodetection showed markedly increased pERK expression in K- 
HeLa cells compared to K+ HeLa cells, especially under control and EGF-stimulated conditions 
(Figures 1 and 2). For both K+ and K- cells, Fas agonist-induced pERK expression was 
comparable (Figure 2).  
 Subsequent experiments using in-cell western assays revealed similar trends to the above. 
That is, K- HeLa cells exhibited higher pERK expression than K+ HeLa cells, but only in 
response to hEGF stimulation (Figures 3 and 4). Expression of pERK was again similar between 
K+ and K- HeLa cells following Fas agonist treatment but was less than that observed for control 
or hEGF treatment conditions (Figure 4). The combination treatment of Fas agonist and hEGF 
restored pERK expression in both cell types to pretreatment levels (Figure 4).  Additionally, the 
overall relative expression of pERK by in-cell western assay was less than that observed by 















 Cytokeratin 8/18 18 filaments protect cells against cytokine-induced death, but their role 
in HeLa cervical cancer cells remains unclear. The current study confirmed that Fas agonist is 
more potent in killing K- HeLa cell than other cytokines, including TNF and TRAIL 28.  
Moreover, although the activation of the MAP kinase pathway is implicated, it does not appear 
to play a direct role in cytokeratin-mediated protection as reported previously in another cell 
model 13, 19, 26. Similar expression of phosphorylated ERK was observed in both K+ and K- HeLa 
cells following exposure to Fas agonist, indicating little to no effect of cytokeratin filaments on 
the MAP kinase pathway. Alternatively, other signaling pathways, such as the PI3K/Akt 
pathway, may be the primary anti-apoptotic pathway activated by cytokeratin filament in HeLa 
and other types of epithelial cells following Fas agonist treatment 5. Future experiments that 
focus on PI3K/Akt pathway may reveal that K8/18 expression counteracts Fas-mediated 
apoptosis through mechanisms anticipated of the MAP kinase pathway.  
 Regardless of the above observations, clear evidence that differences in pERK expression 
exist between K+ and K- HeLa cells was presented.  More specifically, using hEGF as a positive 
control treatment for phosphorylated ERK expression, we determined that 5 ng/mL of hEGF 
elicits much greater expression of pERK in K- than K+ cells 8, 31. The results suggest that 
cytokeratin filaments may actually impair the MAP kinase pathway in some manner that is not 
decipherable from the current experiments. Repeating these experiments and directly 
determining the relationship between the cytokeratin filaments and MAP kinase is one possible 
direction for future research. Using a cytokine other than Fas agonist or a growth factor related to 
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but not hEGF might also help discern whether the K8/18 filaments inhibit some novel aspect of 
the MAP kinase pathway. 
  Fas agonist treatment, known to induce cell death in K- HeLa cells, combined with 
hEGF negated the effects of Fas agonist alone on pERK expression. This indicates that the 
effects of Fas activation are possibly counteracted by cytokeratin filaments and additional 
pathways beyond MAPK than previously hypothesized. Sarcomas, for example, have been 
shown to avoid Fas ligand-induced apoptosis by stimulating secretion of EGF 16. While it is 
currently unclear whether HeLa cells utilize hEGF to avoid Fas-induced apoptosis, perhaps 
future experiments could focus on this phenomenon. 
 Overall, the results of the current experiments did not support the hypothesis that K8/18 
filaments protect HeLa cells from Fas-mediated apoptosis through activation of the MAP kinase 
pathway. Instead, we suggest these cells are protected by another mechanism, possibly activation 
of the PI3K/Akt pathway, or perhaps some yet undiscovered mechanism that ensures the 












Figure 1: Representative immunoblot for the detection of phosphorylated ERK 1/2 (pERK; red 
bands) and total ERK (totERK; green bands) in K- HeLa cell lysates.  Note higher expression of 
pERK in EGF-treated samples.  Quantification of pERK expression relative to totERK in K+ vs. 
K- cells for the three experiments is depicted below.  
 
 
Figure 2. Effects of Fas agonist (1ug/ml) and EGF (5ng/ml) on phosphorylated ERK (pERK) and 
total ERK (totERK) expression in K+ and K- HeLa cells. K+ cells had less pERK expression 
compared to K- cells, especially under control and EGF-stimulated conditions.  Treatments in 
each experiment were performed in duplicate, and the experiment was repeated three times.  
















































K+ HeLa cells express less phosphorylated ERK than 












Figure 3: Representative In-Cell Western assay for phosphorylated ERK 1/2 and total ERK 
expression in K+ and K- HeLa cells. Phosphorylated ERK 1/2 proteins detected as red; total 
ERK expression detected as green. Quantification of pERK expression relative to totERK in K+ 






Figure 4. Effects of Fas agonist (1ug/ml) and EGF (50ng/ml) on phosphorylated ERK (pERK) 
and total ERK (totERK) expression in K+ and K- HeLa cells. Relative in-cell expression of 
pERK was similar in K+ and K- cells, was impaired by Fas agonist, but rebounded in response to 
EGF stimulation (50ng/ml). Treatments were performed in duplicate, and the experiment was 





























































Phosphorylated ERK expression is similar in K+ and K-
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Treatment Diagram for 6-well Culture Plates 
 
 
The positive control denotes EGF (epidermal growth factor) in 5 ng/mL concentration. Fas 

















HeLa Lysate Protocol (Preparing K+ and K- Lysates for Fluorescent Western 




HeLa cells grown to 70% (or greater) confluence in 6-well plate 
Ice-cold PBS 




1.) Aspirate conditioned medium from 6-well plate and replace with fresh medium. 
2.) Add FasL (1 ug/mL concentration) and rhEGF (5 ng/mL concentration) in 10 uL spike to 
appropriate wells. 
3.) Incubate plate at 37°C and 5% CO2 for 10 minutes. 
4.) At the end of 10 minutes, rinse cells with ice-cold PBS (non-sterile). 
5.) Add 500ul/well ice-cold lysis buffer containing protease inhibitor (10 uL/mL) and phosphatase 
inhibitor (10 uL/mL) cocktails to wells. 
6.) Scrape cells from wells, concentrating lysate into small volume and aspirate into microfuge tubes 
7.)  Further lyse cells by passaging through a 28-gauge needle. 
8.) Centrifuge lysates briefly (pulse spin microfuge) to ensure a pellet forms. 
9.) Sonicate (vortex) samples for 15 seconds each. 
10.) Perform BCA assay to determine protein concentration. 
11.) Centrifuge samples for 5 minutes at 13,000 x g to pellet cell debris. 
12.) Denature proteins by heating samples at 100°C for 5 minutes. 
13.) For low protein concentration, add 1 part 5X sample buffer to 4 parts sample. For high protein 
concentration, add equal amount of 1X sample buffer to sample. 
14.) Store in freezer at -80°C until use. 
 
SDS-PAGE: 
Total protein (25-30 uL) was separated by 10% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and electrically transferred (75 V for 2 hours) to polyvinylidene fluoride 








Western Blotting Protocol 




1. Prepare acrylamide gel according to directions located next to chemical hood (if those are 
not available, follow Gel Casting Protocol from 5/14/13). 
2. Remove comb carefully from gel to ensure that wells don’t break. 
3. Lubricate the grey insulators on the electrophoresis chamber to ensure a good seal. 
4. Remove gel from gel caster and clip onto electrophoresis chamber. 
5. Pour tank buffer into the middle of the chamber to test if the apparatus is leaking. Once it 
has been determined that the seal is good, pour buffer into the bottom of the chamber; do 
not put buffer in between empty plate and chamber. 
6. Load samples (20 uL/well) onto gel carefully; do not use the two outer wells on both 
sides of gel. 
7. Attach the cover and plug in the electrodes. Turn on the power source and adjust settings 
for use. Run the gel at max voltage (all the way clockwise) and current at 20 for one hour. 
 
Gel Transfer: 
1. Cut the PVDF membrane and blotting papers (6) to the size of the gel. 
2. Incubate the PVDF membrane in 100% methanol for 5 minutes. 
3. Next, incubate the PVDF membrane in Towbin transfer buffer for 5 minutes. 
4. When the gel is finished running, remove the gel carefully from the cassette and measure 
it. Cut off one corner of the gel and place the gel in Towbin transfer buffer. Shake the gel 
in buffer for 5 minutes. 
 
Preparation of the Gel Sandwich and Protein Transfer: 
1. Tape a mylar mask in place on the mesh screen in the transfer unit. 
2. Dip a piece of blotting paper in the transfer buffer until it is just wet; place this paper over 
the mylar mask. Ensure that the blotting paper is larger than the hole in the mylar mask. 
3. Use a test tube to remove any air bubbles between the paper and transfer unit. 
4. Repeat steps 2 and 3 with two more pieces of blotting paper. 
5. Place the membrane on the blotting paper and remove any air bubbles. 
6. Carefully place the gel on the membrane; try not to readjust its position as proteins may 
transfer as soon as the gel is placed. Remove any air bubbles. 
7. Dip and place 3 more blotting papers on the sandwich. Remove air bubbles as the blotting 
papers are added. The sandwich should be as follows: 3 blotting papers; 1 membrane; 1 
gel; 3 blotting papers. 
8. Put the cover on the apparatus and plug in the electrodes to the power source. 










Blocking Buffer: For 50 mL, add 2.5 g nonfat dry milk to 50 mL TBS 
TBST: For 1 L, add 1 mL Tween 20 to 1000 mL TBS 
Primary Antibody Dilution Buffer: 10 mL TBST, 0.5 g BSA, 5 uL phospho-p44/42 MAPK (ERK 1/2) 
rabbit mAB, and 5 uL p44/42 MAP Kinase (Total ERK) mouse mAb (1:2,000 dilution) 
Secondary Antibody Dilution Buffer: 20 mL TBST, 1 g nonfat dry milk, 1 uL Dylight 800 (anti-Total 
ERK, 1:20,000 dilution), and 1.5 uL Dylight 680 (anti-ERK 1/2, 1:15,000 dilution) 
 
1. Following protein transfer (from Western Blotting Protocol), rinse the PVDF membrane 
in 100% methanol for 1 minute. 
2. Discard methanol and rinse the membrane with water. 
3. Discard water and rinse the membrane in 1xTBS for 2 minutes and leave the membrane 
in TBS until further steps (never let the membrane DRY!) 
4. Place the membrane in 30 mL Blocking Buffer (TBS with nonfat dry milk) for 1 hour at 
room temperature with gentle shaking. 
5. Dilute the primary antibodies as suggested on the product sheet into 10 mL of primary 
antibody buffer with Tween-20. Add this buffer to the membrane and incubate at 4°C 
overnight with gentle shaking. 
6. Pour off primary antibody dilution buffer (recover buffer; do not discard). 
7. Wash the membrane in 1xTBST 3 times for 5 minutes each with gentle shaking at room 
temperature. 
8. Pour off 1xTBST and add 20 mL secondary antibody diluted as suggested on the product 
sheet. 
9. Incubate the membrane in the Western Blot cylinder for ½ hour in the dark at room 
temperature. (Make sure to protect the membrane from light from now on.) 
10. Wash the membrane with 1xTBST 3 times for 5 minutes each in the dark at room 
temperature. 
11. The membrane should be kept wet until read on the LiCor Odyssey machine. 









Treatment Diagram for 96-well Culture Plates 
 
 
One 96-well plate yields two trials under ideal conditions. CK 8/18 control wells were not treated 














In-Cell Western Protocol (adapted 1/14/14) 
Amanda Berger 
 
Culture and Treatment: 
K+ and K- HeLa cells were cultured until 70-80% confluent.  Cells were treated with 5 ng/mL EGF, 10 
ng/mL EGF, 50 ng/mL EGF, 1 ug/mL Fas agonist (CH11), and 50 ng/mL EGF + 1 ug/mL Fas for non-
control conditions. Following treatment, cells were incubated for 10 minutes in incubator (95% humidity, 
37°C, 5% CO2). Immediately after treatment, cells were fixed and permeabilized. 
Fixation and permeabilization: 
Cells were fixed and permeabilized with 100% methanol (50 uL/well).  Growth medium was removed 
from the microplate by inversion on a paper towel then immediately fixed and permeabilized for 10 
minutes at room temperature with gentle shaking with 50 uL ice-cold methanol per well (methanol added 
down the sides of the wells to avoid cell detachment).  Methanol was removed from the plate by inversion 
on a paper towel then rinsed three times for 5 minutes with gentle shaking with 1X PBS (100 uL/well). 
In-Cell Western 
Cells were blocked for one hour at room temperature with 50 uL blocking buffer (1X PBS / 5% normal 
goat serum / 0.3% Triton X-100) per well.  After blocking buffer, cells were washed 3 times (5 minutes) 
with 1X PBS. Cells were probed overnight at 4C with 50 uL/well primary antibody cocktail against 
Phospho-p44/42 MAPK (ERK 1/2, Cell Signaling Technology, Danvers, MA) diluted 1:200 and p44/42 
MAP Kinase (L34F12, Cell Signaling Technology, Danvers, MA) in antibody dilution buffer (1X PBS / 
1% BSA / 0.3% Triton X-100). Control wells were probed with K18 (CY90, Sigma Aldrich, St. Louis, 
MO) diluted 1:800 and β-Actin (13E5, Cell Signaling Technology, Danvers, MA) diluted 1:200 in 
antibody dilution buffer (1X PBS / 1% BSA / 0.3% Triton X-100) to ensure appropriate K 8/18 
expression in the two phenotypes. Following three washes for 5 minutes with PBS, cells were incubated 
for 1 hour at room temperature in the dark with a cocktail of flurochrome-conjugated anti-mouse and anti-
rabbit secondary antibodies (anti-mouse DyLight 800 and anti-rabbit DyLight 680, Cell Signaling 
Technology, Danvers, MA) diluted 1:2000 and 1:1000, respectively, in antibody dilution buffer.  
Following three washes with PBS, the microplate was scanned using the LI-COR® Odyssey® Classic 








Appendix VII: Undergraduate Research Conference Poster 
 
